Nir Barzilai
Showing 1–2 of 2 transcripts.
- Milken Institute57 min
Turning Back Time: The Science of Aging
Joanne Kenen, Nir Barzilai, Howard Fillit, Christopher Hite, Joan Mannick, Joanne Cannon, Sami, Aditi Ramdurai, San, Sarah Locke
A panel of experts led by Nir Barzilai, Christopher Healy, Howard Federoff, and Joan Manik is advocating for a paradigm shift in geroscience from treating individual chronic conditions to targeting the underlying biology of aging. The group is pursuing "healthspan compression" through concrete initiatives like the TAME metformin trial, TORC1 inhibitor development, and combination therapies designed to delay multiple diseases simultaneously. While regulatory hurdles and ethical concerns regarding long-term drug use remain, these efforts aim to prove that extending healthy life is economically viable and socially transformative.
- Milken Institute58 min
Will You Live to a Healthy 100?
Francis Collins, Nir Barzilai, Elizabeth Blackburn, Pinchas Cohen, Joon Yun
A panel of researchers and investors shifts the longevity paradigm from extending chronological lifespan to maximizing healthspan by treating aging as a primary risk factor for chronic disease. Key figures such as Nir Barzilai, Elizabeth Blackburn, and Jun Jung highlighted actionable strategies including genetic insights from centenarians, the management of senescent cells, and the development of a $7 trillion market focused on restoring homeostatic capacity. These efforts are culminating in the imminent TAME clinical trial, which aims to establish aging as an FDA-recognized disease and unlock pharmaceutical investment for drugs like Metformin and Rapamycin to extend human health by two years.